^
    Back
    Association details:
    Biomarker:KIR3DL2 C336R
    Cancer:T Cell Non-Hodgkin Lymphoma
    Drug:Zarnestra (tipifarnib) (CXCL12 inhibitor, Farnesyl transferase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASH 2019
    Title:

    Proof of Concept for Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL) and CXCL12+ Peripheral T-Cell Lymphoma (PTCL): Preliminary Results from an Open-Label, Phase 2 Study

    Published date:
    11/06/2019
    Excerpt:
    A strong association with the activity of tipifarnib was observed in 8 of the 16 (50%) carrying KIR3DL2 gene variants C336R/Q386E: 50% CR rate, 75% ORR, 100% clinical benefit rate….AITL patients carrying KIR3DL2 gene variants experienced a better outcome with tipifarnib treatment than with prior SOC treatment.
    DOI:
    https://doi.org/10.1182/blood-2019-128513
    Trial ID:
    NCT02464228